Some research that was presented by Professor Nigel Bundred at the European Breast Cancer Conference in Amsterdam, revealed that they have actually tested the effectiveness of a pair of drugs which were known as Herceptin (a.k.a trastuzumab) and Lapatinib.
The use of these two drugs is common in breast cancer treatment already, but this is actually the first time that they had been combined together, as well as used in surgery and chemotherapy too. The discovery found that they had the ability to eliminate some types of breast cancer in a period of 11 days only.
Being funded by Cancer Research UK, they also aimed using these drugs in order to combat a protein which is called HER2 (or human epidermal growth factor receptor 2), which actually affects the growth, as well as division of cancer cells. It is also more possible to return than other types of cancer.
Another thing which makes this treatment so appealing is the fact that it actually eliminates the need for chemotherapy and surgery as well. The temporary side effects, such as hair loss, vomiting, and fatigue are also avoided, which actually makes the treatment less impactful in the body of the patient. Chemotherapy is actually not effective entirely, and it is also not the right choice for a lot of patients, so any other alternatives will be far better.
The Results of The Study
For the purposes of the study, there were selected 257 women with HER2 positive breast cancer and the other half of them have been put on the drug combo and the other half were the control group. They have found that those ones on the drug, about 11% had no cancer cells remaining within just two weeks period and 17% of cases featured dramatically shrunken tumors.
Compared to the group which was given only Herceptin, they were found to have 0% with no trace of cancer cells and just 3% showed a drop in tumor size. Clearly, when combined together, the two drugs have a great effect on breast cancer cells, as opposed to being used on their own.
But, there is actually a problem, as Herceptin’s licensing makes it a drug which is only available for use alongside chemotherapy, but not alone. But, the results provided by this study may help to change that.
Even though there is actually still a lot of work to be done, hopefully, this is one major step taken in the fight against one of the deadliest diseases in the world. With medicine advancing and improving every year, it is entirely possible that it may happen sooner than we think it will.
As seen on educateinspirechange.org